Cellular Logistics is a developer of an acellular biomaterial designed to significantly increase cell survival rates and retention of regenerative medicine therapeutics
Soft tissue regeneration is still a developing field
R&D Focus
Acellular biomaterial
Innovative Solution
Cellular Logistics’s biomaterial is a stand-alone therapeutic for cardiac and tissue regeneration applications and also for providing a cell delivery mechanism for regenerative medicine therapeutics
Solution Effectiveness
Cellular Logistics revitalize damaged heart tissue and improve outcomes for patients
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$1.37M
Last Funding Date
May 30, 2023
Startup Stage
Early-Stage
Lead Investors
National Institutes of Health, Lawrence University, Wisconsin Technology Innovation Initiative, Discovery to Product
People
Founders
Eric Schmuck
Amish Raval
Peiman Hematti
CEO
Alex Vodenlich
Products
Product
CFX, CFX Solus
Demo Product or Complete Product?
Complete Product
Future Plan
Investment Funding
Cellular Logistics is actively seeking collaborative partnerships and investment funding to develop and commercialize combination regenerative medicine therapeutics
M&A and Collabs
Collab
Cellular Logistics Inc. (CL) in Madison, Wisconsin, and Allele Biotechnology Inc.
(ALLELE) in San Diego, California, have entered a collaboration to develop regenerative medicine products to treat
ischemic heart disease
